Persistent Corneal Epithelial Defects (PCEDs) Market Size and Forecast 2028

What are the diagnosis and treatment options commonly available in Persistent Corneal Epithelial Defects (PCEDs)?

The failure of fast re-epithelialization and closure within 10-14 days following corneal damage, even with routine supportive therapy, results in persistent corneal epithelial defects (PEDs or PCEDs). PED awareness has risen recently due to expanded research efforts across the ophthalmology spectrum. However, while the exact prevalence of PED is unknown, several studies have estimated it based on its causal occurrence in conjunction with underlying diseases.

Loss of corneal epithelial cells, delayed epithelialization post-injury, non-healing epithelial defect, and others are some of the symptoms of PEDs, which can be caused by epithelial/limbal, inflammatory, neurotrophic, mechanical, and other reasons.

In addition, infection, stromal ulceration, perforation, scarring, and impaired visual acuity can all result from disruptions in this epithelial layer. According to DelveInsight, the total number of Persistent Corneal Epithelial Defects incident cases in the 7MM in 2020 was estimated to be 241,452.

PCED affects males more than females. Fluorescein instillation is used to monitor the extent, location, and depth of a persistent corneal epithelial defect throughout the evaluation. It takes longer for fluorescein to absorb into the epithelium and stroma in deeper persistent corneal epithelial abnormalities.

A comprehensive physical examination should disclose signs such as anterior chamber inflammation, eyelid anomalies, or diminished corneal sensibility, as in the case of neurotrophic persistent corneal epithelial defects. Moreover, persistent corneal epithelial defects are currently managed using a sequential approach, beginning with conservative measures and advancing to medicinal or surgical therapies if they are recalcitrant.

Lubrication, bandaging soft contact lenses, punctal plugs, debridement, and tarsorrhaphy are all included. Initially, the eye is lubricated aggressively every 1-2 hours with preservative-free artificial tears and ocular ointments. Persistent corneal epithelial abnormalities are also treated with tetracyclines, prophylactic Neurotrophic Keratitis (N.K.) antibiotics, and steroids. Inflammatory Disease tetracyclines have been proven to be beneficial in mending persistent corneal epithelial abnormalities within weeks due to their anticollagenolytic activity, which inhibits MMPs produced by inflammation mediators.

What is the Market Size of Persistent Corneal Epithelial Defects (PCEDs) in terms of value?

The global Persistent Corneal Epithelial Defects (PCEDs) Market is projected to increase at a significant CAGR of 18.50 % in the coming years. In 2021, the global Persistent Corneal Epithelial Defects (PCEDs) market was valued at USD XX million and is anticipated to reach the value of USD XX million by 2028. The demand for Persistent Corneal Epithelial Defects (PCEDs) is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD XX million during the forecast period.

What is the key emerging drug for Persistent Corneal Epithelial Defects (PCEDs)? Nexagon: OcuNexus Therapeutics, Eyevance Pharmaceuticals

It's a first-in-class natural antisense treatment that inhibits connexin43, a cell membrane hemichannel-forming protein (Cx43). Targeting gap junctions may help to minimize immune system reactions that might lead to an inflammatory cascade and enhance corneal epithelial microvasculature and regeneration. Nexagon has a competitive advantage in the United States because it was designated as an orphan medicine by the Food and Drug Clinical Causes.

Interesting Facts about Persistent Corneal Epithelial Defects (PCEDs) Industry

• The increased prevalence of chronic corneal epithelial defect formation is propelling the market forward.
• The market will be fuelled by an aging population that is predisposed to PCED.
• Increased knowledge of disease diagnosis and treatment will create new opportunities for the persistent corneal epithelial defects market to grow.
• Novel techniques for treating/improving disease symptoms are at the heart of developing medicines.
• The development of PED medicines involves a number of significant actors.
• North America region had a significant share in terms of volume as well as value in the global Persistent Corneal Epithelial Defects (PCEDs) market in 2021 and is projected to continue its dominance over the forecast period.
• Aggressive lubrication, punctal occlusion, bandage soft contact lenses, pressure patching, tetracyclines, prophylactic Neurotrophic Keratitis (N.K.) antibiotics, and steroids have a monopoly on the persistent corneal epithelial defects market.
• The market for Persistent Corneal Epithelial Defects (PCEDs) is moderately competitive, with many prominent players.
• Few big players currently dominate the market in terms of market share. The demand for innovative medicines, combined with the lack of significant actors, resulted in increased R&D from the academic-industry cooperation, promoting open innovation and emphasizing PED targeting. Novel medicines are showing promise in the treatment of non-healing corneal epithelium.

Who are the Top 10 players/companies in the Persistent Corneal Epithelial Defects (PCEDs) market in terms of value?

The key players in the global Persistent Corneal Epithelial Defects (PCEDs) market in terms of value includes Dompé Faraceutici S.p.A, Novartis AG, Allergan, Next Biosciences, Katena Products. Inc., Johnson & Johnson Services, Inc., Hunt Valley PhmarmaLAB, Almirall, S.A., Ocular Science, Inc., Kala Pharmaceuticals, Bausch Health, Integra LifeSciences Corporation, Laboratoires THEA S.A.S, Skye Biologics Inc., I-MED Pharma inc., and BioTissue, among other.

These key players are concentrating on new product developments as well as technological innovation to enhance their production in Persistent Corneal Epithelial Defects (PCEDs) to gain competitive market share at a global level. For instance, in April 2019, in the United States, Bausch Health launched LOTEMAX SM (Loteprednol Etabonate Ophthalmic Gel) at 0.38 percent. It's used to alleviate postoperative inflammation and pain after eye surgery.

This launch will aid in the company's expansion into the postoperative ocular inflammation/pain sector. On the other hand, in March 2019, ACUVUE OASYS with Transitions Light Intelligent Technology is now available in the United States, according to Johnson & Johnson Vision Care, Inc. As the product is a first-of-its-kind photochromic contact lens, the new TRANSITIONS in ACUVUE OASYS will help the company grow its market share.

Who are the Top 10 Countries in the Persistent Corneal Epithelial Defects (PCEDs) Market?

In the global Persistent Corneal Epithelial Defects (PCEDs) market, the major countries are the US, Canada, China, Japan, India, Germany, France, Italy, Spain, and the U.K. The largest market share is in the United States.

In the United States, the annual incidence of PED ranges from 25 to 38 cases per 100,000 people. The increased R&D from the academic-industry relationship in this region has resulted in the encouragement of open innovation and prioritizing the targeting of PED due to the desire for novel medicines in the absence of important stakeholders.

In the treatment of persistent corneal epithelium, several medicines that have lately been researched are beginning to show promise. According to studies based on the aetiology of the disease, the annual incidence of PED in the United States is less than 200,000 cases, making it a relatively rare disorder. Ocular herpes simplex can cause PED, epithelial and stromal keratitis, scarring, tissue damage, neovascularization, and glaucoma. The prevalence of ocular herpes simplex in the United States is estimated to be 20.7 per 100,000 person-years. Furthermore, PED after a corneal transplant is estimated to be around 7,558 instances per year in the United States, while PED after a diabetic vitrectomy is estimated to be around 2,480-5,257 cases per year.

Which is the Key end-user segment in the Persistent Corneal Epithelial Defects (PCEDs) Market?

The hospital segment is anticipated to dominate the persistent corneal epithelial defects (PCEDs) over the forecast period. Hospitals are an essential component of the healthcare industry, as well as a significant revenue source for the overall industry, which fuels research and innovation in the field. Various healthcare product manufacturers make remarkable investments in terms of marketing strategies as well as revenue to boost their products and services among hospitals.

As a result, strategic decisions made in the hospital sector have a significant impact on the other industries involved in the healthcare steam. Private hospitals and clinics are experiencing a decrease in inpatient footfalls as a result of the nationwide lockdown, as well as several other factors, which are leading to inadequate utilization of healthcare services by patients and a decrease in medical service volumes, resulting in an acute economic crisis.

What are the Driving Factors for the Persistent Corneal Epithelial Defects (PCEDs) Market?

The rising prevalence of persistent corneal epithelial defect production is propelling the market forward. The market will also be driven by an aging population that is predisposed to PCED. Increasing awareness about disease diagnosis and treatment will create new opportunities that will impact the growth of the persistent corneal epithelial defects treatment market during the forecast period.

Companies and academics are collaborating to assess challenges and identify opportunities for Persistent Epithelial Defect (PED) R&D. The therapies in development are centered on novel approaches to treating/improving disease symptoms. Major players are involved in the development of PED therapies. The introduction of new therapies will have a significant impact on the Persistent Epithelial Defect (PED) market.

What are the Major Restraints for Persistent Corneal Epithelial Defects (PCEDs) Market?

The poor response rate and varied adverse effects of the existing treatment options may limit the growth of the Persistent Corneal Epithelial Defects Market.

In addition, the market for persistent epithelial defects treatments is hampered by onerous regulatory procedures imposed by regulatory bodies on medications and devices. On the other hand, the high expense of treating persistent corneal epithelial abnormalities is projected to stymie market expansion. Furthermore, the persistent corneal epithelial defect market's growth is hampered by a lack of public awareness about the condition.

Which Region Dominated the World Persistent Corneal Epithelial Defects (PCEDs) Market?

In 2021, North America dominated the persistent corneal epithelial defects market due to its well-established healthcare infrastructure and the growing number of medication approvals. One of the primary factors driving the growth of the persistent corneal epithelial defect treatment market is the rising number of people suffering from corneal epithelial defects all over the world.

The rise in the prevalence of dry eye syndrome, as well as the advent of new technology development offering solutions for treating various difficulties induced by the disorder, has accelerated market expansion. The market is likely to rise at a high rate over the forecast period, owing to an increase in mechanical trauma cases.

Moreover, Asia Pacific is expanding at a rapid pace, owing to an increase in the number of geriatrics, rising healthcare costs, and, as a result, an increase in PCED cases hence, driving the growth of the persistent corneal epithelial defects market over the forecast period. In all investigations, the frequency of persistent corneal epithelial defects in the Japanese population and the rising number of elderly people in Japan were shown to be relatively high when compared to reports from other nations. The cost of healthcare per patient in Japan is estimated to be USD 323 million.

Segmentation of Global Persistent Corneal Epithelial Defects (PCEDs) Market-

Global Persistent Corneal Epithelial Defects (PCEDs) Market – By Clinical Causes

• Inflammatory Disease
• Neurotrophic Keratitis (NK)
• Epithelial/Limbal Stem Cell Deficiency
• Others

Global Persistent Corneal Epithelial Defects (PCEDs) Market – By Type

• Device
• Medication

Global Persistent Corneal Epithelial Defects (PCEDs) Market – By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Global Persistent Corneal Epithelial Defects (PCEDs) Market – By End User

• Hospitals
• Home-care
• Specialty Clinics
• Others

Rising Prevalence of Chronic Corneal Epithelial Defects

The increasing incidence of chronic corneal epithelial defects, particularly among aging populations and those with underlying ocular or systemic diseases, is driving demand for effective PCED treatments.

Advancements in Diagnosis and Treatment Awareness

Expanded research efforts and greater awareness among healthcare professionals and patients are leading to earlier diagnosis and more aggressive management of PCEDs, fueling market growth.

Development of Novel Therapeutics and Technologies

The introduction of innovative therapies such as antisense treatments (e.g., Nexagon) and advanced devices is expanding the range of available options, attracting investment and accelerating market expansion.

Strong Hospital Sector Demand

Hospitals remain the primary end users for PCED treatments due to the complexity of care required, and their strategic investments in new technologies and therapies are significantly boosting market growth.

Increased R&D and Academic-Industry Collaboration

Collaborative efforts between academic institutions and industry players are fostering open innovation, leading to the development of new medicines and devices specifically targeting persistent corneal epithelial defects.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.